Skip to main content
EVGN
NASDAQ Life Sciences

Subsidiary Biomica's Cancer Drug Shows Favorable Safety, Clinical Activity in Phase 1 Study

Tom Rudovsky · Reported by Reuters
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$0.94
Mkt Cap
$8.267M
52W Low
$0.65
52W High
$2.42
52W Position info
45% above low
Off High info
61% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

EVGN sits 45% above its 52-week low of $0.65.

Summary

Evogene's subsidiary Biomica successfully completed a Phase 1 clinical study for its live bacterial product, BMC128, in combination with Nivolumab. The study met its primary endpoint, demonstrating favorable safety with no dose-limiting toxicities and preliminary signals of clinical activity. This positive development comes amidst a challenging period for Evogene, which recently received a Nasdaq delisting notice, disclosed going concern doubts, and terminated a project with Bayer. The successful Phase 1 trial provides a much-needed positive data point for the company's pipeline.

At the time of this announcement, EVGN was trading at $0.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.3M. The 52-week trading range was $0.65 to $2.42. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

EVGN - Latest Insights

EVGN
Nov 19, 2026, 7:12 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $0.3233
Real-time Price: $0.3162 info
Change: -$0.0071 (-2%) info
Market Cap: $5.708M info
EVGN
Nov 16, 2026, 7:01 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $0.3646
Real-time Price: $0.3162 info
Change: -$0.0484 (-13%) info
Market Cap: $5.708M info
EVGN
Oct 06, 2026, 4:00 PM EDT
Source: PR Newswire
Importance Score:
9
Price at Filing: $0.4101
Real-time Price: $0.3162 info
Change: -$0.0939 (-23%) info
Market Cap: $5.708M info
EVGN
Sep 30, 2026, 7:15 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.4168
Real-time Price: $0.3162 info
Change: -$0.1006 (-24%) info
Market Cap: $5.708M info
EVGN
Sep 28, 2026, 4:10 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $0.3907
Real-time Price: $0.3162 info
Change: -$0.0745 (-19%) info
Market Cap: $5.708M info